Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anemia 4Uterine Cervical Neoplasms 2Myelodysplastic Syndromes 2Leukemia 2Rectal Neoplasms 1Radiation Injuries 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma 1Lichen Planus, Oral 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Erectile Dysfunction 1Drug-Related Side Effects and Adverse Reactions 1Bronchiolitis Obliterans Syndrome 1

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Erythropoietin × Clear all
NCT00254436 2018-10-25

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡